Mirvetuximab soravtansine

Drug Profile

Mirvetuximab soravtansine

Alternative Names: Anti-FOLR1-monoclonal-antibody-maytansinoid-conjugate-IMGN-853; IMGN-853; M9346A-sSPDB-DM4; M9346A-sulfo-SPDB-DM4

Latest Information Update: 21 Jun 2017

Price : $50

At a glance

  • Originator ImmunoGen
  • Developer ImmunoGen; National Comprehensive Cancer Network
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Folate receptor 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Breast cancer
  • Phase I/II Endometrial cancer
  • Phase I Solid tumours

Most Recent Events

  • 05 Jun 2017 Phase-II clinical trials in Breast cancer (Monotherapy, Newly diagnosed, Second-line therapy or greater, Metastatic disease) in USA (IV) (NCT03106077)
  • 17 May 2017 Initial efficacy data from the phase Ib/II FORWARD II trial in Ovarian cancer released by ImmunoGen
  • 17 May 2017 Pooled analysis efficacy data from a phase I trial in Ovarian cancer released by ImmunoGen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top